Journal Article
. 2011 Nov;13(6).
doi: 10.1186/bcr3051.

Protein expression, survival and docetaxel benefit in node-positive breast cancer treated with adjuvant chemotherapy in the FNCLCC-PACS 01 randomized trial

Jocelyne Jacquemier 1 Jean-Marie Boher  Henri Roche  Benjamin Esterni  Daniel Serin  Pierre Kerbrat  Fabrice Andre  Pascal Finetti  Emmanuelle Charafe-Jauffret  Anne-Laure Martin  Mario Campone  Patrice Viens  Daniel Birnbaum  Frédérique Penault-Llorca  François Bertucci  
Affiliations
  • PMID: 22044691
  •     54 References
  •     8 citations

Abstract

Introduction: The PACS01 trial has demonstrated that a docetaxel addition to adjuvant anthracycline-based chemotherapy improves disease-free survival (DFS) and overall survival of node-positive early breast cancer (EBC). We searched for prognostic and predictive markers for docetaxel's benefit.

Methods: Tumor samples from 1,099 recruited women were analyzed for the expression of 34 selected proteins using immunohistochemistry. The prognostic and predictive values of each marker and four molecular subtypes (luminal A, luminal B, HER2-overexpressing, and triple-negative) were tested.

Results: Progesterone receptor-negativity (HR = 0.66; 95% CI 0.47 to 0.92, P = 0.013), and Ki67-positivity (HR = 1.53; 95% CI 1.12 to 2.08, P = 0.007) were independent adverse prognostic factors. Out of the 34 proteins, only Ki67-positivity was associated with DFS improvement with docetaxel addition (adjusted HR = 0.51, 95% CI 0.33 to 0.79 for Ki67-positive versus HR = 1.10, 95% CI 0.75 to 1.61 for Ki67-negative tumors, P for interaction = 0.012). Molecular subtyping predicted the docetaxel benefit, but without providing additional information to Ki67 status. The luminal A subtype did not benefit from docetaxel (HR = 1.16, 95% CI 0.73 to 1.84); the reduction in the relapse risk was 53% (HR = 0.47, 95% CI 0.22 to 1.01), 34% (HR = 0.66, 95% CI 0.37 to 1.19), and 12% (HR = 0.88, 95% CI 0.49 to 1.57) in the luminal B, HER2-overexpressing, and triple-negative subtypes, respectively.

Conclusions: In patients with node-positive EBC receiving adjuvant anthracycline-based chemotherapy, the most powerful predictor of docetaxel benefit is Ki67-positivity.

Postoperative dose-dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high-risk operable breast cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology Group.
G Fountzilas, D Skarlos, +18 authors, A-M Dimopoulos.
Ann Oncol, 2005 Sep 09; 16(11). PMID: 16148021
Microtubule-associated protein-tau is a bifunctional predictor of endocrine sensitivity and chemotherapy resistance in estrogen receptor-positive breast cancer.
Fabrice Andre, Christos Hatzis, +7 authors, Lajos Pusztai.
Clin Cancer Res, 2007 Apr 04; 13(7). PMID: 17404087
Evaluation of the prognostic value of HER-2 and VEGF in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotherapy.
Ioannis Kostopoulos, Petroula Arapantoni-Dadioti, +17 authors, George Fountzilas.
Breast Cancer Res Treat, 2006 Mar 16; 96(3). PMID: 16538542
Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer.
Donald A Berry, Constance Cirrincione, +9 authors, Eric P Winer.
JAMA, 2006 Apr 13; 295(14). PMID: 16609087    Free PMC article.
Highly Cited.
Benefit of taxanes as adjuvant chemotherapy for early breast cancer: pooled analysis of 15,500 patients.
Emilio Bria, Cecilia Nistico, +7 authors, Diana Giannarelli.
Cancer, 2006 May 02; 106(11). PMID: 16649217
Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen.
M Martín, A Lluch, +17 authors, J R Mel.
Ann Oncol, 2006 Jun 13; 17(8). PMID: 16766587
Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.
Soonmyung Paik, Gong Tang, +11 authors, Norman Wolmark.
J Clin Oncol, 2006 May 25; 24(23). PMID: 16720680
Highly Cited.
Predictive factors for response to docetaxel in human breast cancers.
Shinzaburo Noguchi.
Cancer Sci, 2006 Jun 30; 97(9). PMID: 16805818
Review.
Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer.
Maggie C U Cheang, Stephen K Chia, +10 authors, Torsten O Nielsen.
J Natl Cancer Inst, 2009 May 14; 101(10). PMID: 19436038    Free PMC article.
Highly Cited.
Ki67 expression and docetaxel efficacy in patients with estrogen receptor-positive breast cancer.
Frédérique Penault-Llorca, Fabrice André, +11 authors, Henri Roché.
J Clin Oncol, 2009 Apr 22; 27(17). PMID: 19380452
Is there a standard type and duration of adjuvant chemotherapy for early stage breast cancer?
Daniel F Hayes.
Breast, 2009 Nov 17; 18 Suppl 3. PMID: 19914531
FEC versus sequential docetaxel followed by epirubicin/cyclophosphamide as adjuvant chemotherapy in women with axillary node-positive early breast cancer: a randomized study of the Hellenic Oncology Research Group (HORG).
Aristides Polyzos, Nikolaos Malamos, +14 authors, Dimitris Mavroudis.
Breast Cancer Res Treat, 2009 Jul 29; 119(1). PMID: 19636702
Identification of biology-based breast cancer types with distinct predictive and prognostic features: role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapy.
Silvia Darb-Esfahani, Sibylle Loibl, +15 authors, Gunter von Minckwitz.
Breast Cancer Res, 2009 Sep 18; 11(5). PMID: 19758440    Free PMC article.
Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial.
Henri Roché, Pierre Fumoleau, +17 authors, Bernard Asselain.
J Clin Oncol, 2006 Nov 23; 24(36). PMID: 17116941
Highly Cited.
Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011.
A Goldhirsch, W C Wood, +4 authors, Panel members.
Ann Oncol, 2011 Jun 29; 22(8). PMID: 21709140    Free PMC article.
Highly Cited.
Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients.
E de Azambuja, F Cardoso, +7 authors, M Paesmans.
Br J Cancer, 2007 Apr 25; 96(10). PMID: 17453008    Free PMC article.
Highly Cited.
HER2 and response to paclitaxel in node-positive breast cancer.
Daniel F Hayes, Ann D Thor, +14 authors, Cancer and Leukemia Group B (CALGB) Investigators.
N Engl J Med, 2007 Oct 12; 357(15). PMID: 17928597
Highly Cited.
Taxanes for adjuvant treatment of early breast cancer.
T Ferguson, N Wilcken, +2 authors, A K Nowak.
Cochrane Database Syst Rev, 2007 Oct 19; (4). PMID: 17943815
Systematic Review.
Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials.
Michele De Laurentiis, Giuseppe Cancello, +13 authors, Sabino De Placido.
J Clin Oncol, 2008 Jan 01; 26(1). PMID: 18165639
Highly Cited.
Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial.
Prudence Francis, John Crown, +17 authors, BIG 02-98 Collaborative Group.
J Natl Cancer Inst, 2008 Jan 10; 100(2). PMID: 18182617
Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer.
Giuseppe Viale, Meredith M Regan, +16 authors, International Breast Cancer Study Group.
J Natl Cancer Inst, 2008 Jan 31; 100(3). PMID: 18230798
Gene expression patterns in formalin-fixed, paraffin-embedded core biopsies predict docetaxel chemosensitivity in breast cancer patients.
Jenny C Chang, Andreas Makris, +14 authors, Steven Shak.
Breast Cancer Res Treat, 2007 May 01; 108(2). PMID: 17468949
Estrogen receptor expression and efficacy of docetaxel-containing adjuvant chemotherapy in patients with node-positive breast cancer: results from a pooled analysis.
Fabrice Andre, Kristine Broglio, +5 authors, Lajos Pusztai.
J Clin Oncol, 2008 May 30; 26(16). PMID: 18509176
Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
Miguel Martín, Alvaro Rodríguez-Lescure, +33 authors, GEICAM 9906 Study Investigators.
J Natl Cancer Inst, 2008 May 29; 100(11). PMID: 18505968
Proliferation markers and survival in early breast cancer: a systematic review and meta-analysis of 85 studies in 32,825 patients.
R Stuart-Harris, C Caldas, S E Pinder, P Pharoah.
Breast, 2008 May 06; 17(4). PMID: 18455396
Highly Cited. Systematic Review.
Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197.
Lori J Goldstein, Anne O'Neill, +4 authors, Nancy E Davidson.
J Clin Oncol, 2008 Aug 06; 26(25). PMID: 18678836    Free PMC article.
Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole.
Giuseppe Viale, Anita Giobbie-Hurder, +18 authors, Breast International Group Trial 1-98.
J Clin Oncol, 2008 Nov 05; 26(34). PMID: 18981464    Free PMC article.
Highly Cited.
Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735.
Stephen Jones, Frankie Ann Holmes, +17 authors, Michael A Savin.
J Clin Oncol, 2009 Feb 11; 27(8). PMID: 19204201
Highly Cited.
Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial.
Judith Hugh, John Hanson, +11 authors, Charles Vogel.
J Clin Oncol, 2009 Feb 11; 27(8). PMID: 19204205    Free PMC article.
Highly Cited.
Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial.
Paul Ellis, Peter Barrett-Lee, +22 authors, TACT Trialists.
Lancet, 2009 May 19; 373(9676). PMID: 19447249    Free PMC article.
Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer.
Luca Gianni, José Baselga, +15 authors, Gianni Bonadonna.
J Clin Oncol, 2009 Apr 01; 27(15). PMID: 19332727
Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer.
Heikki Joensuu, Pirkko-Liisa Kellokumpu-Lehtinen, +22 authors, FinHer Study Investigators.
N Engl J Med, 2006 Feb 24; 354(8). PMID: 16495393
Highly Cited.
Predictive value of p53, mdm-2, p21, and mib-1 for chemotherapy response in advanced breast cancer.
J Sjöström, C Blomqvist, +10 authors, E Saksela.
Clin Cancer Res, 2000 Aug 24; 6(8). PMID: 10955790
A graphical method to assess treatment-covariate interactions using the Cox model on subsets of the data.
M Bonetti, R D Gelber.
Stat Med, 2000 Sep 15; 19(19). PMID: 10986536
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications.
T Sørlie, C M Perou, +14 authors, A L Børresen-Dale.
Proc Natl Acad Sci U S A, 2001 Sep 13; 98(19). PMID: 11553815    Free PMC article.
Highly Cited.
Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: preliminary data of a prospective randomized trial.
Aman U Buzdar, S Eva Singletary, +19 authors, Gabriel N Hortobagyi.
Clin Cancer Res, 2002 May 15; 8(5). PMID: 12006521
Weekly docetaxel as neoadjuvant chemotherapy for stage II and III breast cancer: efficacy and correlation with biological markers in a phase II, multicenter study.
Laura G Estévez, José Miguel Cuevas, +6 authors, José Fortes.
Clin Cancer Res, 2003 Feb 11; 9(2). PMID: 12576436
Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer.
I Craig Henderson, Donald A Berry, +16 authors, Larry Norton.
J Clin Oncol, 2003 Mar 15; 21(6). PMID: 12637460
Highly Cited.
Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis.
A F Wahl, K L Donaldson, +4 authors, D A Galloway.
Nat Med, 1996 Jan 01; 2(1). PMID: 8564846
Highly Cited.
Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients.
T Aas, A L Børresen, +5 authors, P E Lønning.
Nat Med, 1996 Jul 01; 2(7). PMID: 8673929
Highly Cited.
Protein expression profiling identifies subclasses of breast cancer and predicts prognosis.
Jocelyne Jacquemier, Christophe Ginestier, +11 authors, François Bertucci.
Cancer Res, 2005 Feb 12; 65(3). PMID: 15705873
Phase III randomized trial of doxorubicin and docetaxel versus doxorubicin and cyclophosphamide as primary medical therapy in women with breast cancer: an anglo-celtic cooperative oncology group study.
T R Jeffry Evans, Ann Yellowlees, +12 authors, Janine L Mansi.
J Clin Oncol, 2005 Apr 30; 23(13). PMID: 15860854
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG).
Lancet, 2005 May 17; 365(9472). PMID: 15894097
Highly Cited.
Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28.
Eleftherios P Mamounas, John Bryant, +7 authors, Norman Wolmark.
J Clin Oncol, 2005 May 18; 23(16). PMID: 15897552
Highly Cited.
Adjuvant docetaxel for node-positive breast cancer.
Miguel Martin, Tadeusz Pienkowski, +30 authors, Breast Cancer International Research Group 001 Investigators.
N Engl J Med, 2005 Jun 03; 352(22). PMID: 15930421
Highly Cited.
Proliferation marker Ki-67 in early breast cancer.
Ander Urruticoechea, Ian E Smith, Mitch Dowsett.
J Clin Oncol, 2005 Sep 30; 23(28). PMID: 16192605
Highly Cited. Review.
Taxanes: optimizing adjuvant chemotherapy for early-stage breast cancer.
Philippe L Bedard, Angelo Di Leo, Martine J Piccart-Gebhart.
Nat Rev Clin Oncol, 2009 Dec 10; 7(1). PMID: 19997076
Review.
Gene expression profiling of breast cancer.
Lajos Pusztai.
Breast Cancer Res, 2010 Jan 20; 11 Suppl 3. PMID: 20030862    Free PMC article.
Cyclophosphamide, epirubicin, and Fluorouracil versus dose-dense epirubicin and cyclophosphamide followed by Paclitaxel versus Doxorubicin and cyclophosphamide followed by Paclitaxel in node-positive or high-risk node-negative breast cancer.
Margot Burnell, Mark N Levine, +11 authors, Lois E Shepherd.
J Clin Oncol, 2009 Nov 11; 28(1). PMID: 19901117    Free PMC article.
Recommendations for research priorities in breast cancer by the Coalition of Cancer Cooperative Groups Scientific Leadership Council: systemic therapy and therapeutic individualization.
Joseph A Sparano, Gabriel N Hortobagyi, +2 authors, Robert L Comis.
Breast Cancer Res Treat, 2009 Jun 16; 119(3). PMID: 19526354
Ki67 in breast cancer: prognostic and predictive potential.
Rinat Yerushalmi, Ryan Woods, +2 authors, Karen A Gelmon.
Lancet Oncol, 2010 Feb 16; 11(2). PMID: 20152769
Highly Cited. Review.
Predictive markers of anthracycline benefit: a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601).
John M S Bartlett, Alison F Munro, +13 authors, Christopher J Poole.
Lancet Oncol, 2010 Jan 19; 11(3). PMID: 20079691
Molecular predictors of efficacy of adjuvant weekly paclitaxel in early breast cancer.
Miguel Martín, Alvaro Rodríguez-Lescure, +18 authors, Enrique de Alava.
Breast Cancer Res Treat, 2009 Dec 29; 123(1). PMID: 20037779
BCIRG 001 molecular analysis: prognostic factors in node-positive breast cancer patients receiving adjuvant chemotherapy.
Charles Dumontet, Maryla Krajewska, +5 authors, John C Reed.
Clin Cancer Res, 2010 Jun 26; 16(15). PMID: 20576719
Do we need biomarkers to predict the benefit of adding adjuvant taxanes for treatment of breast cancer?
José Pérez-García, Javier Cortés.
Breast Cancer Res, 2012 Feb 03; 14(1). PMID: 22297134    Free PMC article.
Differential response of immunohistochemically defined breast cancer subtypes to anthracycline-based adjuvant chemotherapy with or without paclitaxel.
George Fountzilas, Urania Dafni, +18 authors, Meletios A Dimopoulos.
PLoS One, 2012 Jun 09; 7(6). PMID: 22679488    Free PMC article.
Triple-negative breast cancer: bridging the gap from cancer genomics to predictive biomarkers.
S Lindsey Davis, S Gail Eckhardt, John J Tentler, Jennifer R Diamond.
Ther Adv Med Oncol, 2014 May 03; 6(3). PMID: 24790649    Free PMC article.
Review.
Evaluation of Ki67 expression across distinct categories of breast cancer specimens: a population-based study of matched surgical specimens, core needle biopsies and tissue microarrays.
Gøril Knutsvik, Ingunn M Stefansson, +4 authors, Lars A Akslen.
PLoS One, 2014 Nov 07; 9(11). PMID: 25375149    Free PMC article.
Optimal systemic therapy for early breast cancer in women: a clinical practice guideline.
A Eisen, G G Fletcher, +5 authors, members of the Early Breast Cancer Systemic Therapy Consensus Panel.
Curr Oncol, 2015 Apr 08; 22(Suppl 1). PMID: 25848340    Free PMC article.
Adjuvant chemotherapy for early female breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guideline.
S Gandhi, G G Fletcher, +4 authors, M E Trudeau.
Curr Oncol, 2015 Apr 08; 22(Suppl 1). PMID: 25848343    Free PMC article.
Review.
Immunohistochemical subtypes predict the clinical outcome in high-risk node-negative breast cancer patients treated with adjuvant FEC regimen: results of a single-center retrospective study.
S Rahal, J M Boher, +12 authors, A Gonçalves.
BMC Cancer, 2015 Oct 16; 15. PMID: 26466893    Free PMC article.
Biological subtyping of early breast cancer: a study comparing RT-qPCR with immunohistochemistry.
Ralph M Wirtz, Harri Sihto, +12 authors, Heikki Joensuu.
Breast Cancer Res Treat, 2016 May 26; 157(3). PMID: 27220750    Free PMC article.